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Recent preclinical studies in rodent models of diabetes suggest that exogenous GLP-1R agonists and DPP-4 inhibitors have the
ability to increase islet mass and preserve beta-cell function, by immediate reactivation of beta-cell glucose competence, as well as
enhanced beta-cell proliferation and neogenesis and promotion of beta-cell survival. These eﬀects have tremendous implication
in the treatment of T2D because they directly address one of the basic defects in T2D, that is, beta-cell failure. In human diabetes,
however, evidence that the GLP-1-based drugs alter the course of beta-cell function remains to be found. Several questions
surrounding the risks and beneﬁts of GLP-1-based therapy for the diabetic beta-cell mass are discussed in this review and require
further investigation.
1.The RationaleforRestorationofBeta-Cell
MassinDiabetic Patients
Both type 1 and type 2 diabetes are characterised by deﬁcits
in beta-cell mass (∼99% deﬁcit in long-standing type 1
diabetes, ∼65% deﬁcit in long-standing type 2 diabetes
[1]). There is little doubt regarding the importance of
increased autoimmune-mediated beta-cell death in type 1
diabetes, and recent studies in type 2 diabetes suggest that
the frequency of beta-cell apoptosis is also signiﬁcantly
increased, although other factors cannot be excluded, such
as the failure of beta-cell mass to expand adequately in
response to rising secretory demands by adapting beta-
cell replication and neogenesis. Loss of beta-cells in both
types of diabetes implies that restoration of endogenous
insulin secretion and normalisation of hyperglycemia in
such patients might be accomplished through the sup-
plementation of islet cells. Indeed, hyperglycemia in both
t y p e so fd i a b e t e si sr e v e r s e db yp a n c r e a st r a n s p l a n t a t i o n ,
and intraportal transplantation of isolated islets temporarily
restores glucose control. Unfortunately, replacement of beta-
cell mass by islet or pancreas transplantation is associated
with both surgical morbidity and the adverse eﬀects of
chronic immunosuppression. Some of the risks and side
eﬀects, including ischemic and enzymatic damage caused by
the islet isolation and puriﬁcation protocol as well as the
concerns of thrombosis and portal hypertension induced by
transplanting islets into the liver portal vein, are intrinsic
to the islet transplantation procedure itself [2]. Moreover,
there is an insuﬃcient supply of pancreases available for the
increasing number of people with diabetes, thus preventing
the widespread implementation of this intervention. There
is, therefore, a need for alternative approaches for restoring
functional beta-cell mass in patients with diabetes.
Conceivable approaches to achieve beta-cell supplemen-
tation consist of restoring an endogenous source and/or im-
planting an autologous- or nonautologous-derived source.
At present, there are diﬀerent strategies under investigation:
(1) transplantation of beta cells generated in vitro from
nonautologous embryonic stem cells, (2) transplantation of
beta-cells generated in vitro from patient’s own adult stem
cells, and (3) stimulation of beta-cell regeneration in vivo
from patient’s own endogenous cell sources.
An alternative strategy for the restoration of beta-cell
mass in patients with diabetes is to foster in vivo beta-cell
regeneration from patient’sendogenouscell sources. There is2 Experimental Diabetes Research
now evidence that beta-cell mass is dynamic and capable of
undergoing adaptive changes in response to diﬀerent secre-
tory demands. In humans, beta-cell mass increases by ∼50%
in obesity, and both insulin secretion and beta-cell mass have
been shown to increase in pregnant women [3]. Likewise,
beta-cell mass in rodents increases by ∼2.5-fold towards the
end of pregnancy and is rapidly decreased through increased
apoptosis and reduced replication postpartum. In humans,
the overall capacity for beta-cell replication is much lower
than in rodents, and very few replicating beta cells (one cell
in ∼50 islets of ∼100 beta-cells each per cross-section) can
be found in adult human pancreas [1]. There is, however,
a capacity for increased beta-cell replication in humans:
beta-cell replication has been reported to be more than
ten times higher in human pancreas adjacent to gastrin-
producing tumours [4] and in the pancreas of an old patient
with recent-onset type 1 diabetes [5]. Indeed, the emerging
understanding of beta-cell growth in the adult, either
from precursor cells found in the pancreatic ducts or/and
from residual beta cells, holds the promise of developing
new strategies for stimulating beta-cell regeneration. Such
approach necessitates the delivery of appropriate growth fac-
tors to these cells to obtain a full beta-cell phenotype. GLP-
1 could be one of the most promising candidates for doing
so. The following sections review our current understanding
of the therapeutic potential of the GLP-1 receptor (GLP-1R)
agonists for the diabetic beta-cell population.
2.Activationofthe GLP-1RSignalling Pathway
and Beta-CellFunctions
GLP-1 replenishes beta-cell insulin stores via increased
insulin mRNAstability, gene transcription, and biosynthesis.
It stabilizes mRNA encoding preproinsulin, thereby stabiliz-
ing and upregulating its expression [6, 7]. GLP-1 increases
insulin gene transcription and biosynthesis via activation of
both PKA-dependent and -independent signalling pathways.
PDX-1, the most extensively studied insulin transcription
factor, is a key eﬀector for the GLP-1R signaling pathway
on insulin gene transcription and biosynthesis, as well as
diﬀerentiation, proliferation, and survival of the beta cell.
GLP-1 has been shown, both in vitro and in vivo, to be
involved in regulation of PDX-1 by increasing its total
protein levels, and its translocation to the nucleus, followed
by its binding to the A-box element and the GG2 element of
the rat and human insulin promoters and resultant increase
in activity of the insulin gene promoter in beta cells [8–
13]. The regulation of PDX-1 by GLP-1 mainly occurrs via
cAMP/PKA-dependentsignalingpathway[10].Nevertheless,
GLP-1 triggers expression and nuclear localization of PDX-1
involves the phosphorylation of FoxO1 via transactivation of
the EGFR and PI-3K/PKB pathway, resulting in deactivation
and nuclear exclusion of FoxO1 and consequent disinhi-
bition of Foxa2-dependent pdx-1 gene promoter activity
[14, 15]. In addition, FoxO1 and PDX-1 mutually exclude
eachotherfrom thenucleusofthebetacell[14].TheGLP-1R
signaling pathway also mediates insulin gene transcription
via basic region-leucine zipper transcription factors that are
related structurally to the transcription factor CREB, and
thesedirectly bindtoCREsites ontheinsulin genepromoter.
This eﬀect is independent of Gsα, cAMP/PKA, and PKC and
m a yb em e d i a t e db yt h e9 0 - k D ar i b o s o m a lS 6k i n a s ea n d
mitogen- and stress-activated protein kinase family of CREB
kinases [16, 17].
GLP-1 is one of the most potent substances known to
stimulate glucose-induced insulin secretion (GIIS), and its
stimulatory activity is exerted via binding to its receptor
on beta cells. This binding results in activation of adenylyl
cyclase with consequent production of cAMP and sub-
sequent activation of PKA and the Epac family. GLP-1-
mediated activation of PKA results in phosphorylation of
the SUR1 KATP channel subunit via an ADP-dependent
mechanism, facilitating its closure [18]. This is followed
by membrane depolarization and triggering of the insulin
secretory pathway. Treatment with the PKA inhibitor 8-
bromoadenosine-3 ,5 -cyclic mono-phosphorothioate, Rp-
isomer[19],orH89[18]abolishesGLP-1-inducedinhibition
of the KATP channels. SUR1(−/−)i s l e t sl a c ka ni n s u l i n
secretoryresponse butexhibitanormalriseincAMPtoGLP-
1, implicating cAMP-dependent PKA-independent signal
transduction pathway [20, 21]. It is now clear that the
action of cAMP produced by GLP-1 signaling is mediated
n o tj u s tb yP K A ,b u ta l s ob yE p a c 2[ 22, 23], and Epac2
also inhibits the function of KATP channels in rodent
and human beta-cells via interaction with SUR1 [24, 25].
A recent study has also demonstrated that the scaﬀold
protein, β-arrestin-1, facilitates GLP-1-stimulated cAMP
production via interaction with GLP-1R [26]. GLP-1 signal-
ing also antagonizes voltage-dependent K+ (Kv) channels
via cAMP/PKA-dependent pathway in beta cells, which
prevents beta-cell repolarization by reducing Kv currents
[27]. However, MacDonald et al., [27] identiﬁed a role of PI-
3K with subsequent activation of PKCζ in the antagonism
of the Kv current by GLP-1. This occurred via epidermal
growth factor receptor (EGFR) transactivation, not via the G
protein-regulated isoform p110γ [27]. L-type Ca2+ channels
are also phosphorylated by PKA, leading to increase of
their open probability and enhancement of Ca2+ inﬂux [28–
30]. Activation of GLP-1R also increases intracellular Ca2+
throughCa2+-releasefromtheendoplasmicreticulumviathe
inositol 1,4,5 triphosphate receptors activated by PKA and
the ryanodine receptors activated by Epac2 [31, 32]. A recent
study has indicated that GLP-1 elevates intracellular Ca2+
concentration via stimulation of the nicotinic acid adenine
dinucleotide phosphate and cyclic ADP-ribose production
[33], catalyzed by cyclic ADP-ribose cyclases, that stimulates
glucose-induced Ca2+ mobilization [34]. Direct eﬀects of
GLP-1 signaling on insulin-containing vesicles have also
been described. Lester et al. [35]p r o p o s e dam e c h a n i s m
by which changes in insulin secretion are associated with
phosphorylation of the vesicle-associated protein synapsin-
1 by PKA followed by dephosphorylation by calcineurin
[35]. PKA may also regulate the vesicle priming through the
phosphorylation of RIM proteins [36]. It is known that RIM
proteins bind Rab3a, which serves to tether the vesicle to the
plasma membrane [37] and also bind Munc13-1 to create
a link between synaptic vesicle tethering and priming [38].
RIM proteins also bind Epac2, and this binding participatesExperimental Diabetes Research 3
in the regulation ofdockingand fusion of insulin-containing
vesiclesto the plasma membrane [39, 40].In addition, Epac2
interactswithPicollo,aRIM2-interactingproteinoninsulin-
containing vesicles, in a Ca2+-dependent manner [41].
Intracellular cAMP levels have long been recognized to
becritical fornormal GIIS(glucose-competence)[42].Thus,
receptors linked to cAMP production, such as the GLP-1R
play an important role to control cellular cAMP levels. It has
been very recently proposed that the biological process regu-
lated by GLP-1 to control the beta-cell glucose competence
was dependent on the level of IGF-1R expression and on
IGF-2 secretion [43]. Finally, since GLP-1 also stimulates the
expression of GLUT2 transporters and glucokinase, which
determine the rate of glycolysis, it helps to confer glucose
competence to beta cells and thereby increase the eﬃcacy
(maximal eﬀect) and potency (threshold concentration) of
glucoseas astimulusforinsulinsecretion[44]. However,this
interpretation is questionable in the light of recent extensive
data indicating that GLP-1 barely aﬀects beta-cell interme-
diary metabolism and that metabolic signalling does not
signiﬁcantly contribute to GLP-1 potentiation of GIIS [45].
3.PharmacologicalActivationofthe GLP-1R
Signalling PathwayinGlucose-Insensitive
DiabeticBeta Cells
Enhancement of GIIS from the beta cell is one of principal
goals for treatment of patients with T2D. Because the mech-
anism underlying the insulinotropic action of GLP-1 in an in
vitro model of glucose-unresponsive beta cells (dispersed rat
beta cells) has been shown to involve activation of adenylate
cyclaseand cAMPproduction[42], we investigated the eﬀect
of GLP-1 stimulation on cAMP production and GIIS in
GK/Par rats with spontaneous T2D [46]. Diabetic GK/Par
islets were able to amplify their cAMP content in response
to GLP-1 in the presence of high glucose, and this was
associated with a strong insulin release with restitution of
their insulin secretory competence to glucose [47]. GLP-1-
stimulated cAMPgenerationwas instrumental inthe GLP-1-
triggered insulin release at high glucose since insulin release
became no longer reactive to GLP-1 when AC isoforms
were acutely blocked by the AC blocker dd-Ado. Since we
also demonstrated that GK/Par beta cells suﬀer from some
degree of cAMP-resistance, one may conclude that GLP-1
at pharmacological dosage, is able to generate within the
GK/Par beta cell, cAMP levels high enough to cope for the
reduced eﬀectiveness of cAMP [47]. Furthermore, we report
that GLP-1 also normalizes GIIS in islets from n-STZ rats
(another recognized model of rat diabetes with glucose-
unresponsive beta cells) [48]. This suggests that restoration
by GLP-1 of glucose responsiveness in the diabetic beta cell
is not restricted to the GK model, but is probably a more
generalized mechanism.
4.Activation of the GLP-1R Signalling Pathway
and Beta-CellGrowth/Survival
Repair or expansion of the beta-cell population can be
achieved through stimulation of beta-cell proliferation
and/or neogenesis, and slowing the rate of beta-cell apop-
tosis. Abundant in vitro and in vivo studies have shown
that GLP-1, and its analogs such as Exendin-4 (Ex-4) are
capable of inducing beta-cell proliferation in normal rodent
islets and insulinoma cell lines [49–52]. This proliferative
seems toinvolvethe activation ofimmediate early genes such
as c-jun, junD, nur77, and c-fos [53], and the implication
of diﬀerent intermediary signaling molecules such as PI3K,
PKB/Akt, and PKCzeta [53, 54]. Studies in INS-1 cells
have also indicated that betacellulin- (BTC-) mediated
transactivation of the epidermal growth factor receptor/erb-
B1 is a prerequisite for GLP-1-induced proliferative eﬀectsin
these cells [49]. However, BTC failed to induce proliferation
in a diﬀerent insulinoma cell line, RINm5F and also in
fetal human beta cells [55] .T h ei m p o r t a n c eo ft h eP d x 1
transcription factor in mediating the proliferative eﬀects of
GLP-1 in beta cells was demonstrated using mice with beta
cell-speciﬁc inactivation of the Pdx1 gene. Ex-4-mediated
proliferation was blocked in isolated islets from these mice,
suggesting that Pdx1expression is essential for Ex-4-induced
proliferative eﬀects [51]. Interestingly, Ex-4 induces Pdx1
expression in human fetal islet cell cultures and promotes
functional maturation and proliferation of human islet cell
cultures transplanted under the rat kidney capsule [56].
It has become clear that GLP-1 acts by means of Gsα
and PI-3K/PKB to stimulate beta cell proliferation and
survival. A beta-cell-speciﬁc Gsα deﬁciency in mice results
in diabetes characterized by reduced insulin secretion and
beta-cell mass with the primary defect being in decreased
beta-cell proliferative capacity [57]. It has been also shown
that GLP-1 inhibits FoxO1 transcriptional activity through
phosphorylation-dependent nuclear exclusion in beta cells
[15], and the ability of Ex-4 to increase beta-cell mass was
blunted in transgenic mice expressing constitutively nuclear
FoxO1 in beta cells [15]. FoxO1 inactivation plays an impor-
tant role in the eﬀect of GLP-1 on the expression of the two
important transcription factors PDX-1and Foxa2[16].GLP-
1 activation of PI-3K/PKB facilitates acute nuclear translo-
cation of existing PDX-1. Indeed, mice with a beta-cell-
speciﬁc inactivation of PDX-1 do not display a proliferative
response toEx-4 treatment [51].GLP-1 activationofPI-3Kis
mediated by transactivation of EGFRs via GLP-1R-mediated
activation of c-Src that in turn activates a membrane-bound
metalloproteinase, with concomitant release of the soluble
ligand BTC which is an agonist of EGFRs [49]. This is also
followed by activation and translocation to the nucleus of
PKCζ, resulting in enhancement of the stimulatory eﬀect
of GLP-1 on beta-cell proliferation [53]. GLP-1 also exerts
its stimulatory eﬀects on beta-cell proliferation through
CREB-mediated Irs2 gene expression, leading to activation
of PI-3K/PKB [58]. GLP-1R activation has been shown to
upregulate the expression of cyclin D1 [59, 60], and this
eﬀect is likely to be mediated by PKA-dependent activation
of CREB [60, 61]. A recent study showed that GLP-1R sig-
naling via cAMP/PKA activates β-catenin/T-cell factor-like
2- (TCF7L2-) dependent Wnt signaling in the proliferation
throughupregulationofcyclinD1[62].Aprominentrolefor
β-cateninTCF7L2-dependentWnt signaling is now acknowl-
edged after the reports that GSK-3β overexpression in mice4 Experimental Diabetes Research
induces beta cell mass restriction and the development of
diabetes [63], that genetic disruption of GSK-3β in beta-
cells results in increased beta-cell mass and that beta-cell
regeneration can be promoted by systemic administration
of GSK-3β inhibitors to streptozotocin-induced neonatal
diabetic rats [64]. Unexpectedly, the proliferative eﬀect
of GLP-1 was recently related to IGF-1R expression and
autocrine secretion of IGF-2 by the beta-cell, since this eﬀect
was suppressed by Igf-1r gene inactivation and by IGF-2
immunoneutralization or knockdown [43].
GLP-1R activation reducesbeta-cell apoptosis inpuriﬁed
rodent and human islets as well as beta-cell lines after
exposure to many cytotoxicagents, includingreactive oxygen
species, glucose, free fatty acid, palmitate, cytokines, tumor
necrosis factor-α (TNF-α), immunosuppressive reagents,
and dexamethasone [66]. A role for endogenous GLP-1
in prevention of beta-cell death was demonstrated by the
increased susceptibility to streptozotocin-induced apopto-
sis in GLP-1R knockout mice; conversely, streptozotocin-
induced apoptosis was signiﬁcantly reduced by coadminis-
tration of Ex-4 [67]. Ex-4 also reduces biochemical markers
of islet ER stress in vivo and ER stress-associated beta-
cell death in a PKA-dependent manner [68, 69]. Similar to
GLP-1-induced beta-cell proliferation, antiapoptotic eﬀects
of GLP-1 in beta cells are mediated by promotion of FoxO1
nuclear exclusion and consequent upregulation of PDX-1
andFoxa2expressionviaEGFR-andPI3K-dependentactiva-
tion of PKB and cAMP/PKA-dependent activation of CREB,
leading to upregulation of IRS2 protein expression and acti-
vation of PKB. Also similar to the induction of proliferation,
activation of IGF-1 receptor expression and IGF-2 secretion
participate to the GLP-1-induced the protection of the beta
cells against cytokine-induced apoptosis, through [43]. The
protective eﬀect of GLP-1 on beta-cell glucolipotoxicity is
alsomediatedbyPKBactivationandpossiblyitsdownstream
target nuclear factor-κB[ 70]. In addition, recent studies
suggest that GLP-1R agonists protect beta cells from proin-
ﬂammatory cytokine-induced apoptosis by inhibiting the c-
Jun NH2-terminal kinase pathway via upregulation of islet-
brain 1, a potent blocker of the c-Jun NH2-terminal kinase
pathway [71], and activation of the extracellular signal-
regulated kinase 1/2-dependent pathway [72].
GLP-1R was conﬁrmed to be present in pancreatic ducts
in mouse, rat, and human [73, 74]. GLP-1R exists in the
AR42J acinar cell line derived from a rat pancreatic tumor
and treatment with GLP-1 or Ex-4 causes increases in both
intracellular cAMP and Ca2+ levels [75]. Activation of GLP-
1R signaling either in ductal or acinar cell lines or in vivo
in rodents has resulted in diﬀerentiation of a fraction of
these cells toward an islet-like phenotype, in association
with activation of PKC and MAPK, and transcription factors
necessary for an endocrine phenotypesuch as PDX-1, as well
as the glucose-sensing factors glucokinase and GLUT2 [76].
GLP-1R activation of those cells also aﬀects transforming
growth factor-β signaling pathways, resulting in reduced
Smad activity [77, 78]. AR42J cells, even without GLP-1R
a c t i v a t i o n ,h a v et h ep o t e n t i a lt ob ec o n v e r t e di n t oe n d o c r i n e
[79] but are negative for islet hormones and their transcripts
under usual culture conditions [76]. When these cells were
exposed to GLP-1 or Ex-4, approximately 20% of the cells
contained insulin protein and were capable of releasing
insulin in a glucose-mediated mode [76]. Such GLP-1 eﬀect
was also observed in Capan-1 cell line [80] and rat ARIP and
human PANC-1 cell lines. Similar to the AR42J cells, GLUT2
and glucokinase transcripts were induced in these cell lines
[81]. In particular, the diﬀerentiation-promoting activity of
GLP-1 requires the expression of PDX-1, because PANC-
1 cells, which lack endogenous PDX-1, diﬀerentiate only
when transfected with PDX-1, whereas rat ARIP cells that
express PDX-1 are susceptible to undergoing diﬀerentiation
into insulin-secreting cells [81]. In the Capan-1 cell line,
diﬀerentiation to insulin-producing cells was also seen when
they were transfected with PDX-1, and PDX-1 antisense
totally inhibited such conversion [80]. In human pancreatic
ducts also where GLP-1 receptor is abundantly expressed,
Ex-4 treatment in vitro increases the number of insulin-
producing cells. This suggests that GLP-1/Ex-4 is useful to
facilitate beta-cell neogenesis in adult pancreatic ducts [74].
5.PharmacologicalActivationofthe GLP-1R
Signalling PathwayinModelsofDeﬁcient
Beta-CellMass
Acute or chronic treatment of diabetic rodents with GLP-
1R agonists stimulates beta-cell proliferation and neogenesis
and slows the rate of beta-cell apoptosis, leading to an
expansion of beta-cell mass. In vivo administration of GLP-
1, Ex-4 or other degradation-resistant analogs has been
shown to increase beta-cell mass in diﬀerent prediabetic
and diabetic rodent models [11, 65, 82–86]. Administration
of GLP-1 or Ex-4 for several days resulted in stimulated
expansion of beta-cell mass and increased beta-cell pro-
liferation in old glucose-intolerant rats [84], adult db/db
mice, Zucker rats, pancreatectomized rats and mice, or
intrauterine growth-retardedrats [87].A transient treatment
o fG L P - 1o rE x - 4i nS T Z - t r e a t e dn e w b o r nr a t sr e s u l t e di na
sustained improvement of beta-cell mass through increased
beta-cell neogenesis and replication [83]( F i g u r e1). We
obtained similar conclusion in the nSTZ model after in vivo
administration of a DPPIV inhibitor (Figure 2). Moreover,
diabetic Lepdb/Lepdb mice treated with Ex-4 for 2 weeks
showed enhanced expressionofPDX-1intheducts(favoring
the presence of GLP-1R in ductal cells, as referenced above)
and the exocrine tissue [11], which means that GLP-1R
agonists aid in islet neogenesis, because ductal cells have
beenthoughttobe the mainsource forendocrine neogenesis
[88].
Taking advantage of the GK/Par rat model of sponta-
neous T2D, we have raised the question of what is the
impact of GLP-1 or Ex-4 treatment, in terms of beta-cell
mass enlargement and long-term improvement of glucose
homeostasis. To address this issue, we investigated the ability
of GLP-1 or Ex-4 treatment to promote beta-cell prolifera-
tion in young GK/Par rats during the prediabetic stage and
thereby to prevent the pathological progression of the T2D
when animals become adults. GK/Par rats were submitted
to GLP-1 or Ex-4 injection from postnatal day 2 to day 6
only [84]. Both treatments enhanced, on day 7, pancreaticExperimental Diabetes Research 5
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Figure 1: GLP-1 or Exendin-4 (Ex-4) activates beta-cells regeneration in vivo. The aim was to investigate in the rat model of neonatal
beta-cell regeneration (nSTZ model), the capacity of in vivo treatments with GLP-1 or Ex-4 to promote beta-cell regeneration. To this
end, nSTZ rats from the Wistar strain (W) were submitted to GLP-1 or Ex-4 administration from postnatal day 2 to day 6 only, and their
beta-cell masses were tested on day 7 (a) and (b). In the nSTZ/GLP-1 and nSTZ/Ex-4 groups, total beta-cell masses per pancreas were both
signiﬁcantlyincreased (∗∗∗P<. 001)ascompared withvaluesin untreated nSTZrats,representing, respectively, 51%and71%ofthecontrol
Wistar beta-cell mass, while nSTZ beta-cell mass represented only 21% of the control Wistar value. Beta-cell BrdU labeling index (c) in the
untreated nSTZ rats was found to be signiﬁcantly increased (P<. 001) as compared with Wistar group. In the nSTZ/GLP-1 and nSTZ/Ex-4
groups, it was similarly increased. A representative ﬁgure is given with double immunostaining for BrdU and insulin in 7-day-old nSTZ
rats (magniﬁcation ×1000). To estimate activation of neogenesis (d) and (e), the number of single beta-cells incorporated into the duct
epithelium and the number of beta-cell clusters budding from ducts were quantiﬁed. The number of isolated beta-cell within pancreatic
tissueofnSTZ rats represented 185%ofWistarvalueand the number ofbeta-cell buds in pancreatic tissuein nSTZ rats represented 106%of
Wistarvalue.Thesetwoparameterswere stronglyincreasedinnSTZ/GLP-1andnSTZ/Ex-4ratsascomparedtountreated nSTZrats(∗∗∗P<
.001). A representative ﬁgure is given with indirect immunoperoxydase staining for insulin in 7 day-old nSTZ/GLP-1 rats (magniﬁcation
×1000). Adapted from Tourrel et al. [83].6 Experimental Diabetes Research
0
50
100
100
200
300
β
-
c
e
l
l
m
a
s
s
(
c
o
n
t
r
o
l
%
)
P
I
.
g
l
u
c
o
s
e
(
c
o
n
t
r
o
l
%
)
Birth (d0) STZ
07
(day)
+ DPP4I
(a)
0
0.2
0.4
0.6
0.8
1
β
-
c
e
l
l
m
a
s
s
(
m
g
/
p
a
n
c
r
e
a
s
)
∗∗
∗
W
/
d
7
+
s
a
l
i
n
e
,
n
=
8
n
S
T
Z
/
d
7
+
s
a
l
i
n
e
,
n
=
8
n
S
T
Z
/
d
7
+
L
A
F
2
3
7
,
1
0
m
g
/
k
g
,
n
=
8
n
S
T
Z
/
d
7
+
S
3
8
0
1
3
,
1
0
m
g
/
k
g
,
n
=
8
n
S
T
Z
/
d
7
+
E
x
4
,
3
m
g
/
k
g
,
n
=
5
(b)
0
50
100
150
200
250
B
a
s
a
l
P
I
.
g
l
u
c
o
s
e
(
m
g
/
m
L
)
∗∗
∗
∗∗
W
/
d
7
+
s
a
l
i
n
e
,
n
=
8
n
S
T
Z
/
d
7
+
s
a
l
i
n
e
,
n
=
8
n
S
T
Z
/
d
7
+
L
A
F
2
3
7
,
1
0
m
g
/
k
g
,
n
=
8
n
S
T
Z
/
d
7
+
S
3
8
0
1
3
,
1
0
m
g
/
k
g
,
n
=
8
n
S
T
Z
/
d
7
+
E
x
4
,
3
m
g
/
k
g
,
n
=
5
(c)
Figure 2: DPPIV inhibitors activate beta-cells regeneration in vivo. The aim was to investigate in the rat model of neonatal beta-cell
regeneration (nSTZ model), the capacity of in vivo treatment by DPPIV inhibitors (LAF237 or S38013) to promote beta-cell regeneration.
To this end, nSTZ rats were submitted to DPPIVadministration from postnatal day 2 to day 6 only,and their beta-cell masseswere tested on
day 7. Ex-4 was taken as a beta-cell growth stimulator comparator. In the 7-day-old untreated nSTZ group, total beta-cell mass per pancreas
was only 22% of the value in the untreated normalgroup (P<. 001). In the nSTZ/LAF237 group, the total beta-cell mass increase (by 46%)
did not reach statistical signiﬁcance. In the nSTZ/S38013 group, the total beta-cell mass increase (by 68%) reached statistical signiﬁcance
(∗P<. 05). Beta-cell mass in the nSTZ/Ex-4 group was twice increased (∗∗P<. 01). In the 7-day-old untreated nSTZ group, basal plasma
glucosevaluewassigniﬁcantlyincreased by 70%(P<. 05)ascompared to thatofuntreated normalgroup. By contrast,in the nSTZ/LAF237,
nSTZ/S38013, and nSTZ/Ex-4 groups, basal plasma glucose levels were signiﬁcantly decreased (P<. 05 or P<. 01) at the end of treatment
as compared with those in the untreated nSTZ group and reached values no longer signiﬁcantly diﬀerent from those in untreated normal
pups.
insulin contents and total beta-cell mass by stimulating both
beta-cell neogenesis and beta-cell regeneration. Followup of
biological characteristics from day 7 to adult age (2 months)
showed that both treatment exerted long-term favorable
inﬂuence on beta-cell mass and glycaemic control at adult
age. As compared to untreated GK/Par rats, 2-month-old
GLP-1 or Ex-4-treated GK rats exhibited improved glucose-
stimulatedinsulinsecretion,invivoafterintravenousglucose
load or in vitro using isolated perfused pancreas. Moreover,
plasma glucose disappearance rate was increased in both
treated GK/Par groupscompared to untreated GK/Par group
[84]. These ﬁndings model indicate that a GLP-1 or Ex-
4 treatment limited to the prediabetic period, delays the
installation, and limits the severity of T2D in the GK/Par
model.
GLP-1R activation also promotes preservation and
expansion of beta-cell mass in type 2 diabetic rodent models
throughprotecting betacellsagainst thedeleteriouseﬀectsof
the diabetic milieu (i.e., increased cytokine toxicity, glucose
toxicity, and lipotoxicity). Ex-4 treatment of Lepdb/Lepdb
mice decreases activation of caspase-3 and prevents beta-cell
apoptosis through PKB and MAPK [85]a n di n f u s i o nw i t h
GLP-1 drastically reduced the number of apoptotic beta cells
in islets of Zuckerdiabetic rats [65].
Collectively, the studies above mentioned so far indicate
that GLP-1R agonists may prove useful for expansion of
human beta cells either cultured in vitro, after transplan-
tation, or after sustained treatment of diabetic subjects in
vivo.
6.CurrentIssuesThatChallenge
theBeneﬁcialEffectsofGLP-1R
AgonistsforBeta-Cell Therapy
6.1. Risk of Pancreatic Tumor Formation in Patients Receiving
GLP-1R Agonist Supplementation. If GLP-1R agonists were
to be used continuously to treat diabetes, then uncontrolled
beta-cell proliferation would become an issue unless there
were brakes on the system. Klinger et al. [89] shed light on
cellular mechanisms that may indeed limit the proliferative
eﬀect of GLP-1 in beta-cells: GLP-1 provides its own brakes
because it leads to the rapid and strong expression of four
negative regulators of intracellular signalling: RGS2 (regu-
lator of G protein signalling 2), Dusp14 (dual-speciﬁcity
phosphatase 14, also called MAP kinase phosphatase 6, a
negative feedback regulator of the mitogen-activated protein
kinase signaling cascade), Icer (inducible cAMP early repres-
sor), and Crem-α (cAMP responsive element modulator
alpha).However, anobviousquestiontobe furtherstudiedis
whether unrestrained beta-cell proliferation may result from
loosening of the GLP-1 eﬀect upon these negative regulators
of beta-cell growth, during long-term treatment.Experimental Diabetes Research 7
6.2. Risk of Pancreatitis in Patients Receiving GLP-1R Agonist
Supplementation. Another concern with respect to clinical
use of GLP-1 relates to reports of pancreatitis in some
patients long-term treated with long-acting GLP-1 recep-
tor agonists [90]. However, amylase levels and pancreatic
markersofinﬂammationwerefoundreducedinEx-4-treated
mice, and Ex-4 did not increase the severity of pancreatitis
in a murine model of this condition [91]. Furthermore, no
evidencewas found foran increased incidenceofpancreatitis
in a large cohort of patients treated with either exenatide or
sitagliptin, compared with those treated with metformin or
glyburide [92]. Notwithstanding, a recent paper in the HIP
diabeticratmodeltreatedwithsitagliptinhasreportedductal
cell hyperplasia in all sitagliptin-treated animals, acinar to
ductal metaplasia in some, and haemorrhagic pancreatitis
in one isolated case [93]. Histologic evidence of pancreatic
acinar inﬂammation has also been found in rats treated with
Ex-4 and their acinar cells were abnormal in appearance and
had a greater frequency of cell death [94]. Pancreatic ductal
replicationis increased in humans with obesity and/or type 2
diabetes[95],providingapossiblelinkbetweentheincreased
risk of pancreatitis in individuals with obesity and/or T2D.
In common with the HIP rat model of diabetes, pancreatic
ductal replication was also increased in humans with obesity
and T2D [95]. The mechanisms that induce increased
pancreatic ductal replication in patients with obesity and/or
type 2 diabetes are unknown. Excessive fat accumulation in
pancreas could induce local inﬂammation [95]. Increased
beta cell apoptosis in type 2 diabetes is also associated with
inﬂammation and increased local cytokines [96]. Such com-
bination might activate islet regeneration via duct-related
progenitors, comparable to the process proposed for acinar
tissue in chronic pancreatitis. GLP-1 therapy may potentially
amplify ductal hyperplasia since it has been reported to acti-
vate pancreatic regenerative eﬀorts with increased duct cells
positive for PDX-1 [74]. Given the clinical gravity of pancre-
atitis, a better understanding of this issue is important.
6.3. Relevance of GLP-1R Agonist Supplementation for T1D.
Althoughregenerative and antiapoptoticactions of GLP-1 or
Ex-4 have been demonstrated in both normoglycemic and
diabetic animal models, the majority of these studies were
conducted in animal models of T2D [83–87]. In contrast,
much less is known about whether the actions of GLP-
1R agonists are maintained in the setting of an ongoing
autoimmune attack, as is the case in the NOD mouse,
the BB rat, and in human subjects with type 1 diabetes
(T1D).Zhangetal.[97]haveshownthatcontinuousdelivery
of GLP-1 via an osmotic minipump in prediabetic NOD
mice results in signiﬁcant increases in beta-cell mass and
replication rate, together with a signiﬁcant reduction in the
rate of beta-cell apoptosis. Hence, it seems possible that
GLP-1R activation may be able to enhance beta-cell mass
even in the presence of an autoimmune attack, if therapy
is initiated before the onset of hyperglycemia. Ex-4 has also
been administered to NOD mice alone or in combination
with diﬀerent immune modulators, lisofylline [98], antilym-
phocyte serum [99], or anti-CD3 immunotherapy [100]:
the highest frequency of diabetes remission was observed in
animals thatreceivedthecombinationtreatments,suggesting
a beneﬁcial synergistic eﬀect between immunomodulators
and the Ex-4 regenerative agent. Furthermore, recent studies
have reported that increasing the levels of circulating GLP-1
byinhibiting dipeptidyl peptidase-4resultsinprolongedislet
graft survival and decreased insulitis in diabetic NOD mice
[101],thatEx-4invitro decreasedIFN-γ-inducedexpression
ofseveralinﬂammatory mediatorsinhumanisletsandMIN6
cells [102] and that Ex-4 in vivo induced a recovery of beta-
cell proliferation during the initial stages of insulitis in the
BB/Worcesterrat [103].The ﬁnding of an anti-inﬂammatory
action of Ex-4 may have implications for the treatment of
both types of diabetes, since the presence of immune cells
in islets from human T2D diabetic patients and from animal
models of T2D has been reported [96].
6.4. No Reliable Method to Assess Beta-Cell Mass in Patients
Receiving GLP-1R Agonist Supplementation. Among the
demonstrated biological actions of GLP-1R agonists, none
has generated more interest than the ﬁndings of enhanced
beta-cell growth and survival in rodent diabetic models
[104]. The possibility that incretin therapy may not only
improve beta-cell function but also increase beta-cell mass
in patients with T2D has, therefore, created much excite-
ment. Determination of the success of therapeutic strategies
designed to enhance beta-cell regeneration requires reliable
methods for the assessment of beta-cell mass. In animal
models, beta-cell mass can be easily calculatedas the product
ofpancreaticweightandthefractionalbeta-cellareaincross-
sections from diﬀerent regions of the pancreas. In human,
there are no direct measures currently available to determine
whether an antidiabetes drug has the ability to alter the
course of T2D by increasing beta-cell mass (replication,
neogenesis) or attenuating beta-cell apoptosis. Noninvasive
imaging techniques that can assess islet mass are currently
being explored, but have not yet reached the sensitivity
that is required for use in humans, and pancreatic tissue
for histological examination cannot be ethically procured
for research purposes only. This leaves no direct means for
testing direct eﬀects of GLP-1-based drugs on beta-cell mass
in diabetic patients.
6.5. Signiﬁcance of the Islet-Derived GLP-1 Source and Its
Modulation by GLP-1R Agonist Supplementation. Beside
production and secretion of GLP-1 by the enteroendocrine
L cells throughout the intestinal epithelium, there is now
growing evidence that under certain conditions, islet alpha-
cellsareanextraintestinal siteforGLP-1production,perhaps
to support the function and/or survival of neighboring beta-
cells. While proglucagon is expressed in islet alpha-cells, PC2
is the predominant processing enzyme in these cells, cleaving
proglucagon to yield glucagon rather than GLP-1. However,
under certain conditions, alpha cells do express PC1/3 and
liberate GLP-1 from proglucagon instead. Several models
of pancreatic injury have been associated with islet GLP-1
production. Treatment of neonatal rats with STZ increases
pancreatic GLP-1 content [105]. STZ treatment of adult
rats increases PC1/3expression inglucagon-immunoreactive
cells in islets and increases GLP-1 levels in islets and8 Experimental Diabetes Research
plasma [106]. It has been shown recently that treatment of
isolated mouse islets with a PC1/3-expressing adenovirus
induces GLP-1 release from alpha cells, increases GIIS, and
promotes islet survival [107]. In addition, transplantation of
PC1/3-expressing alpha-cells increases plasma GLP-1 levels
and improves glucose homeostasis in rodent models of
type 1 and type 2 diabetes [108]. Thus, manipulation of
proglucagon processing in the alpha cell to yield GLP-1
can be wiewed as a startegy for enhancing islet function
and survival. Since GLP-1 seem to be expressed in islets
under certain conditions, it might be necessary to revise
our understanding of how this hormone modulates beta-
cell secretion and growth. Our current view relies on the
network of neural and endocrine signals originating in the
gut after food intake that stimulate insulin secretion. We
should now also consider the possibility that intraislet GLP-
1 signals might modulate insulin secretion and/or inﬂuence
beta-cell survival. Determining the physiological importance
of the islet-derived GLP-1 source during diabetes and its
modulation during administration of exogenous GLP-1R
agonists is a clinically relevant issue.
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